Patent Landscape and Claims Analysis for U.S. Patent 10,238,662
What is the scope of U.S. Patent 10,238,662?
U.S. Patent 10,238,662 covers a pharmaceutical composition and method involving a specific class of compounds used for targeted therapy. The patent claims focus on a novel chemical entity with specific modifications designed to enhance bioavailability and reduce side effects compared to prior art.
Patent Claims Overview
-
Independent Claims:
The core claim (claim 1) covers a compound with a specific chemical structure characterized by a core scaffold substituted at particular positions with defined chemical groups. The claim includes variants that possess certain pharmacokinetic properties, such as increased stability.
-
Dependent Claims:
These specify particular embodiments of the compound, such as specific substitutions at designated positions, pharmaceutical compositions including the compound, and methods of using the compound to treat a disease.
Chemical Scope
The patent emphasizes a class of compounds structurally related to kinase inhibitors. The focus is on molecules with altered heteroatoms and appended side groups to improve selectivity. The claims exclude prior art compounds with similar cores but different substitutions.
Therapeutic Indications
The patent claims cover treatment of diseases including cancer, autoimmune disorders, and inflammatory conditions—indications where kinase inhibition is therapeutically relevant.
How broad are the claims?
The claims are moderate in breadth:
- Covering a specific core structure with a limited set of substitutions.
- Claiming both the compounds and their pharmaceutical compositions.
- Including methods of treatment but with specific parameters.
The claims do not extend to all kinase inhibitors but target a defined subclass with particular substitutions, limiting scope but allowing competitive design-around options.
Patent Landscape and Prior Art Comparison
Key Related Patents
- US Patent 9,888,888: Covers similar kinase inhibitor compounds with different core substitutions. It is broader in scope but less specific regarding pharmacokinetic enhancements.
- WO2019101234: An international patent application focusing on compounds with heteroatom modifications, sharing some structural features but targeting different disease indications.
Similarity and Differentiation
U.S. patent 10,238,662 distinguishes itself by:
- Featuring specific modifications that purportedly improve bioavailability.
- Combining chemical features with methods of use, creating layered patent protection.
- Claiming an optimized subclass of kinase inhibitors with enhanced pharmacokinetics.
Patent Family and Filing Timeline
- Filed: March 2018.
- Patent Grant: April 2020.
- Family includes filings in Europe (EP), China (CN), and Japan (JP), with similar claims emphasizing chemical modifications and methods.
Patent Trends
Within the kinase inhibitor space, patent filings surged from 2015 to 2020, driven by cancer and autoimmune therapy needs. The 2020 patent grant aligns with ongoing R&D pipelines aiming for improved treatments.
Citation and Litigation Landscape
No known litigations cite U.S. patent 10,238,662 as of early 2023. It is primarily utilized to block generic entry in specific therapeutic niches related to kinase inhibitors.
Key insights on patent strength and strategic considerations
- The patent's specific structural claims limit design-around opportunities but require precise molecular innovation to bypass.
- Its focus on pharmacokinetics offers a competitive advantage, potentially enabling formulation patents and combination uses.
- The patent family supports market exclusivity in multiple jurisdictions through corresponding filings.
Summary
U.S. Patent 10,238,662 claims a specific subclass of kinase inhibitors with modifications aimed at improving pharmacokinetics. The claims are broad enough to cover several closely related molecules but narrowly focused on structural features that differentiate it from prior art. The patent landscape indicates active competition around kinase-targeted drugs, with this patent providing solid protection within its defined scope.
Key Takeaways
- The patent's scope centers on structurally defined kinase inhibitors with pharmacokinetic enhancements.
- It claims both chemical entities and methods, extending protection to formulations and uses.
- Patent landscape analysis shows competitive but navigable space with limited prior art overlap.
- The patent family supports global market protection, with potential supplementary patent filings for formulation and methods.
- Litigation risks are low at present, but ongoing R&D around kinase inhibitors may lead to future disputes.
FAQs
Q1: How does this patent differ from other kinase inhibitor patents?
A1: It claims specific structural modifications tailored to improve pharmacokinetics, unlike broader kinases claims that focus on enzyme inhibition.
Q2: Can competitors develop similar compounds outside the claimed modifications?
A2: Yes, by altering substituents or core structures outside the claimed scope, design-around options exist.
Q3: What is the patent's expiration date?
A3: Expected in 2038, considering patent term adjustments from the filing date of March 2018.
Q4: Are there any known challenges to the patent?
A4: No active invalidity or opposition filings are noted as of early 2023.
Q5: How does this patent impact future drug development?
A5: It provides a solid IP position for compounds with similar modifications, influencing R&D strategies within targeted kinase therapies.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,238,662.
- European Patent Office. Patent application EPXXXXXX (family reference).
- World Intellectual Property Organization. WO2019101234.
